-
1 Comment
Innoviva, Inc is currently in a long term uptrend where the price is trading 15.6% above its 200 day moving average.
From a valuation standpoint, the stock is 99.7% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 4.1.
Innoviva, Inc's total revenue rose by 19.1% to $90M since the same quarter in the previous year.
Its net income has increased by 17.3% to $54M since the same quarter in the previous year.
Finally, its free cash flow grew by 27.5% to $85M since the same quarter in the previous year.
Based on the above factors, Innoviva, Inc gets an overall score of 5/5.
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US45781M1018 |
| Sector | Healthcare |
| Industry | Biotechnology |
| PE Ratio | 50.67 |
|---|---|
| Target Price | 19 |
| Beta | 0.49 |
| Market Cap | 1B |
| Dividend Yield | None |
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline), a tetracycline class antibacterial for the treatment of complicated intra-abdominal infections in adults; XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia; and ZEVTERA, a cephalosporin antibacterial for the treatment of adult patients with staphylococcus aureus bloodstream infections, adult patients with acute bacterial skin and skin structure infections, and adult and pediatric patients with community-acquired bacterial pneumonia. Its development pipeline includes Zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for INVA using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
